Ensysce Biosciences Announces Clinical Trial Progress of its New Class of Opioids
November 30, 2021 08:00 ET
|
Ensysce Biosciences Inc.
SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with novel technologies that may...
Ensysce Biosciences Reports Third Quarter 2021 Financial Results and Recent Corporate Updates
November 15, 2021 17:32 ET
|
Ensysce Biosciences Inc.
SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms...
Ensysce Biosciences Announces Completion of $15 Million Convertible Note Financing
November 08, 2021 08:00 ET
|
Ensysce Biosciences Inc.
SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms...
Ensysce Biosciences Grows its Management Team with Appointment of Dr. Linda Pestano as Chief Development Officer
October 26, 2021 08:00 ET
|
Ensysce Biosciences Inc.
SAN DIEGO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical stage biotech company with proprietary technology platforms...
Ensysce Biosciences Announces $15 Million Convertible Note Financing
September 27, 2021 08:00 ET
|
Ensysce Biosciences Inc.
SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology...
Ensysce Biosciences Announces Treatment of First Cohort for Subjects in Clinical Study of its Next Generation Opioid, PF614
September 08, 2021 08:00 ET
|
Ensysce Biosciences Inc.
SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology...
Ensysce Biosciences to Host Satellite Symposium with Dr. Jeffrey Gudin at PAINWeek 2021 on September 9, 2021
August 19, 2021 08:00 ET
|
Ensysce Biosciences Inc.
SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms...
Ensysce Biosciences Reports Second Quarter 2021 Financial Results and Recent Corporate Updates
August 16, 2021 16:45 ET
|
Ensysce Biosciences Inc.
SAN DIEGO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms...
Ensysce Biosciences Announces Notice of Allowance from the U.S. Patent and Trademark Office for Patent Entitled “Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof”
August 05, 2021 08:00 ET
|
Ensysce Biosciences Inc.
SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms...
Ensysce Biosciences Bolsters Management Team with Appointments of David J. Kovacs as VP Public Policy and David Tanzer as VP Strategic Development
July 26, 2021 08:00 ET
|
Ensysce Biosciences Inc.
SAN DIEGO, July 26, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms...